Generic Vosevi Availability

Last updated on Mar 9, 2023.

Vosevi is a brand name of sofosbuvir/velpatasvir/voxilaprevir, approved by the FDA in the following formulation(s):

VOSEVI (sofosbuvir; velpatasvir; voxilaprevir - tablet;oral)

Manufacturer: GILEAD SCIENCES INC
Approval date: July 18, 2017
Strength(s): 400MG;100MG;100MG ^[RLD]

Has a generic version of Vosevi been approved?

No. There is currently no therapeutically equivalent version of Vosevi available in the United States.

Note: Fraudulent online pharmacies may attempt to sell an illegal generic version of Vosevi. These medications may be counterfeit and potentially unsafe. If you purchase medications online, be sure you are buying from a reputable and valid online pharmacy. Ask your health care provider for advice if you are unsure about the online purchase of any medication.

Related patents

Patents are granted by the U.S. Patent and Trademark Office at any time during a drug's development and may include a wide range of claims.

Patent 10,912,814
Patent expiration dates:
- June 1, 2037
  ✓
  Drug product
Patent 11,116,783
Patent expiration dates:
- January 30, 2034
  ✓
  Patent use: TREATMENT OF ADULT PATIENTS WITH CHRONIC HCV INFECTION WHO HAVE GENOTYPE 1, 2, 3, 4, 5, OR 6 INFECTION AND HAVE PREVIOUSLY BEEN TREATED WITH AN HCV REGIMEN CONTAINING AN NS5A INHIBITOR
  ✓
  Drug product
- January 30, 2034
  ✓
  Patent use: TREATMENT OF ADULT PATIENTS WITH CHRONIC HCV INFECTION WHO HAVE GENOTYPE 1A OR 3 INFECTION AND HAVE PREVIOUSLY BEEN TREATED WITH AN HCV REGIMEN CONTAINING SOFOSBUVIR WITHOUT AN NS5A INHIBITOR
  ✓
  Drug product
Patent 11116783*
Patent expiration dates:
- July 30, 2034
Patent 11,338,007
Patent expiration dates:
- June 1, 2037
  ✓
  Patent use: TREATMENT OF ADULT PATIENTS WITH CHRONIC HCV INFECTION WHO HAVE GENOTYPE 1, 2, 3, 4, 5, OR 6 INFECTION AND HAVE PREVIOUSLY BEEN TREATED WITH AN HCV REGIMEN CONTAINING AN NS5A INHIBITOR
  ✓
  Drug product
- June 1, 2037
  ✓
  Patent use: TREATMENT OF ADULT PATIENTS WITH CHRONIC HCV INFECTION WHO HAVE GENOTYPE 1A OR 3 INFECTION AND HAVE PREVIOUSLY BEEN TREATED WITH AN HCV REGIMEN CONTAINING SOFOSBUVIR WITHOUT AN NS5A INHIBITOR
  ✓
  Drug product
Patent 11338007*
Patent expiration dates:
- December 1, 2037
Nucleoside phosphoramidate prodrugs
Patent 7,964,580
Issued: June 21, 2011
Inventor(s): Sofia; Michael Joseph & Du; Jinfa & Wang; Peiyuan
Assignee(s): Pharmasset, Inc.
Disclosed herein are phosphoramidate prodrugs of nucleoside derivatives for the treatment of viral infections in mammals, which is a compound, its stereoisomer, salt (acid or basic addition salt), hydrate, solvate, or crystalline form thereof, represented by the following structure: Also disclosed are methods of treatment, uses, and processes for preparing each of which utilize the compound represented by formula I.
Patent expiration dates:
- March 26, 2029
  ✓
  Patent use: TREATMENT OF ADULT PATIENTS WITH CHRONIC HCV INFECTION WHO HAVE GENOTYPE 1, 2, 3, 4, 5, OR 6 INFECTION AND HAVE PREVIOUSLY BEEN TREATED WITH AN HCV REGIMEN CONTAINING AN NS5A INHIBITOR
  ✓
  Drug substance
  ✓
  Drug product
- March 26, 2029
  ✓
  Patent use: TREATMENT OF ADULT PATIENTS WITH CHRONIC HCV INFECTION WHO HAVE GENOTYPE 1A OR 3 INFECTION AND HAVE PREVIOUSLY BEEN TREATED WITH AN HCV REGIMEN CONTAINING SOFOSBUVIR WITHOUT AN NS5A INHIBITOR
  ✓
  Drug substance
  ✓
  Drug product
- September 26, 2029
  ✓
  Pediatric exclusivity
Nucleoside phosphoramidate prodrugs
Patent 8,334,270
Issued: December 18, 2012
Inventor(s): Sofia; Michael Joseph & Du; Jinfa & Wang; Peiyuan & Nagarathnam; Dhanapalan
Assignee(s): Gilead Pharmasset LLC
Disclosed herein are phosphoramidate prodrugs of nucleoside derivatives for the treatment of viral infections in mammals, which is a compound, its stereoisomer, salt (acid or basic addition salt), hydrate, solvate, or crystalline form thereof, represented by the following structure: Also disclosed are methods of treatment, uses, and processes for preparing each of which utilize the compound represented by formula I.
Patent expiration dates:
- March 21, 2028
  ✓
  Patent use: TREATMENT OF ADULT PATIENTS WITH CHRONIC HCV INFECTION WHO HAVE GENOTYPE 1A OR 3 INFECTION AND HAVE PREVIOUSLY BEEN TREATED WITH AN HCV REGIMEN CONTAINING SOFOSBUVIR WITHOUT AN NS5A INHIBITOR
  ✓
  Drug substance
  ✓
  Drug product
- March 21, 2028
  ✓
  Patent use: TREATMENT OF ADULT PATIENTS WITH CHRONIC HCV INFECTION WHO HAVE GENOTYPE 1, 2, 3, 4, 5, OR 6 INFECTION AND HAVE PREVIOUSLY BEEN TREATED WITH AN HCV REGIMEN CONTAINING AN NS5A INHIBITOR
  ✓
  Drug substance
  ✓
  Drug product
- September 21, 2028
  ✓
  Pediatric exclusivity
Antiviral compounds
Patent 8,575,135
Issued: November 5, 2013
Assignee(s): Gilead Sciences, Inc.
The disclosure is related to anti-viral compounds, compositions containing such compounds, and therapeutic methods that include the administration of such compounds, as well as to processes and intermediates useful for preparing such compounds.
Patent expiration dates:
- November 16, 2032
  ✓
  Patent use: TREATMENT OF ADULT PATIENTS WITH CHRONIC HCV INFECTION WHO HAVE GENOTYPE 1A OR 3 INFECTION AND HAVE PREVIOUSLY BEEN TREATED WITH AN HCV REGIMEN CONTAINING SOFOSBUVIR WITHOUT AN NS5A INHIBITOR
  ✓
  Drug substance
  ✓
  Drug product
- November 16, 2032
  ✓
  Patent use: TREATMENT OF ADULT PATIENTS WITH CHRONIC HCV INFECTION WHO HAVE GENOTYPE 1, 2, 3, 4, 5, OR 6 INFECTION AND HAVE PREVIOUSLY BEEN TREATED WITH AN HCV REGIMEN CONTAINING AN NS5A INHIBITOR
  ✓
  Drug substance
  ✓
  Drug product
- May 16, 2033
  ✓
  Pediatric exclusivity
Nucleoside phosphoramidate prodrugs
Patent 8,580,765
Issued: November 12, 2013
Assignee(s): Gilead Pharmasset LLC
Disclosed herein are phosphoramidate prodrugs of nucleoside derivatives for the treatment of viral infections in mammals, which is a compound, its stereoisomer, salt (acid or basic addition salt), hydrate, solvate, or crystalline form thereof, represented by the following structure: Also disclosed are methods of treatment, uses, and processes for preparing each of which utilize the compound represented by formula I.
Patent expiration dates:
- March 21, 2028
  ✓
  Patent use: TREATMENT OF ADULT PATIENTS WITH CHRONIC HCV INFECTION WHO HAVE GENOTYPE 1A OR 3 INFECTION AND HAVE PREVIOUSLY BEEN TREATED WITH AN HCV REGIMEN CONTAINING SOFOSBUVIR WITHOUT AN NS5A INHIBITOR
  ✓
  Drug substance
  ✓
  Drug product
- March 21, 2028
  ✓
  Patent use: TREATMENT OF ADULT PATIENTS WITH CHRONIC HCV INFECTION WHO HAVE GENOTYPE 1, 2, 3, 4, 5, OR 6 INFECTION AND HAVE PREVIOUSLY BEEN TREATED WITH AN HCV REGIMEN CONTAINING AN NS5A INHIBITOR
  ✓
  Drug substance
  ✓
  Drug product
- September 21, 2028
  ✓
  Pediatric exclusivity
Nucleoside phosphoramidates
Patent 8,618,076
Issued: December 31, 2013
Assignee(s): Gilead Pharmasset LLC
Disclosed herein are nucleoside phosphoramidates and their use as agents for treating viral diseases. These compounds are inhibitors of RNA-dependent RNA viral replication and are useful as inhibitors of HCV NS5B polymerase, as inhibitors of HCV replication and for treatment of hepatitis C infection in mammals.
Patent expiration dates:
- December 11, 2030
  ✓
  Patent use: TREATMENT OF ADULT PATIENTS WITH CHRONIC HCV INFECTION WHO HAVE GENOTYPE 1A OR 3 INFECTION AND HAVE PREVIOUSLY BEEN TREATED WITH AN HCV REGIMEN CONTAINING SOFOSBUVIR WITHOUT AN NS5A INHIBITOR
  ✓
  Drug substance
  ✓
  Drug product
- December 11, 2030
  ✓
  Patent use: TREATMENT OF ADULT PATIENTS WITH CHRONIC HCV INFECTION WHO HAVE GENOTYPE 1, 2, 3, 4, 5, OR 6 INFECTION AND HAVE PREVIOUSLY BEEN TREATED WITH AN HCV REGIMEN CONTAINING AN NS5A INHIBITOR
  ✓
  Drug substance
  ✓
  Drug product
- June 11, 2031
  ✓
  Pediatric exclusivity
Nucleoside phosphoramidates
Patent 8,633,309
Issued: January 21, 2014
Assignee(s): Gilead Pharmasset LLC
Disclosed herein are nucleoside phosphoramidates and their use as agents for treating viral diseases. These compounds are inhibitors of RNA-dependent 5 RNA viral replication and are useful as inhibitors of HCV NS5B polymerase, as inhibitors of HCV replication and for treatment of hepatitis C infection in mammals.
Patent expiration dates:
- March 26, 2029
  ✓
  Patent use: TREATMENT OF ADULT PATIENTS WITH CHRONIC HCV INFECTION WHO HAVE GENOTYPE 1, 2, 3, 4, 5, OR 6 INFECTION AND HAVE PREVIOUSLY BEEN TREATED WITH AN HCV REGIMEN CONTAINING AN NS5A INHIBITOR
  ✓
  Drug substance
  ✓
  Drug product
- March 26, 2029
  ✓
  Patent use: TREATMENT OF ADULT PATIENTS WITH CHRONIC HCV INFECTION WHO HAVE GENOTYPE 1A OR 3 INFECTION AND HAVE PREVIOUSLY BEEN TREATED WITH AN HCV REGIMEN CONTAINING SOFOSBUVIR WITHOUT AN NS5A INHIBITOR
  ✓
  Drug substance
  ✓
  Drug product
- September 26, 2029
  ✓
  Pediatric exclusivity
Nucleoside phosphoramidate prodrugs
Patent 8,735,372
Issued: May 27, 2014
Assignee(s): Gilead Pharmasset LLC
Disclosed herein are phosphoramidate prodrugs of nucleoside derivatives for the treatment of viral infections in mammals, which is a compound, its stereoisomer, salt (acid or basic addition salt), hydrate, solvate, or crystalline form thereof, represented by the following structure: Also disclosed are methods of treatment, uses, and processes for preparing each of which utilize the compound represented by formula I.
Patent expiration dates:
- March 21, 2028
  ✓
  Patent use: TREATMENT OF ADULT PATIENTS WITH CHRONIC HCV INFECTION WHO HAVE GENOTYPE 1A OR 3 INFECTION AND HAVE PREVIOUSLY BEEN TREATED WITH AN HCV REGIMEN CONTAINING SOFOSBUVIR WITHOUT AN NS5A INHIBITOR
  ✓
  Drug substance
  ✓
  Drug product
- March 21, 2028
  ✓
  Patent use: TREATMENT OF ADULT PATIENTS WITH CHRONIC HCV INFECTION WHO HAVE GENOTYPE 1, 2, 3, 4, 5, OR 6 INFECTION AND HAVE PREVIOUSLY BEEN TREATED WITH AN HCV REGIMEN CONTAINING AN NS5A INHIBITOR
  ✓
  Drug substance
  ✓
  Drug product
- September 21, 2028
  ✓
  Pediatric exclusivity
Compositions and methods for treating hepatitis C virus
Patent 8,889,159
Issued: November 18, 2014
Assignee(s): Gilead Pharmasset LLC
Disclosed herein are a composition and unit dosage form for the treatment of hepatitis C virus (HCV) infection comprising GS-7977 and at least one pharmaceutically acceptable excipient, as well as methods for making said composition and unit dosage form. Also disclosed herein is a method of treating a subject, preferably a human, infected with hepatitis C virus, said method comprising administering to the subject for a time period an effective amount of GS-7977 and an effective amount of ribavirin. In one aspect, the method comprises administering to the subject an interferon-free treatment regimen comprising an effective amount of GS-7977 and an effective amount of ribavirin. In a particular aspect, the method is sufficient to produce an undetectable amount of HCV RNA in the subject for at least 12 weeks after the end of the time period.
Patent expiration dates:
- March 26, 2029
  ✓
  Patent use: TREATMENT OF ADULT PATIENTS WITH CHRONIC HCV INFECTION WHO HAVE GENOTYPE 1A OR 3 INFECTION AND HAVE PREVIOUSLY BEEN TREATED WITH AN HCV REGIMEN CONTAINING SOFOSBUVIR WITHOUT AN NS5A INHIBITOR
  ✓
  Drug substance
  ✓
  Drug product
- March 26, 2029
  ✓
  Patent use: TREATMENT OF ADULT PATIENTS WITH CHRONIC HCV INFECTION WHO HAVE GENOTYPE 1, 2, 3, 4, 5, OR 6 INFECTION AND HAVE PREVIOUSLY BEEN TREATED WITH AN HCV REGIMEN CONTAINING AN NS5A INHIBITOR
  ✓
  Drug substance
  ✓
  Drug product
- September 26, 2029
  ✓
  Pediatric exclusivity
Antiviral compounds
Patent 8,921,341
Issued: December 30, 2014
Assignee(s): Gilead Pharmasset LLC
The disclosure is related to anti-viral compounds, compositions containing such compounds, and therapeutic methods that include the administration of such compounds, as well as to processes and intermediates useful for preparing such compounds.
Patent expiration dates:
- November 16, 2032
  ✓
  Patent use: TREATMENT OF ADULT PATIENTS WITH CHRONIC HCV INFECTION WHO HAVE GENOTYPE 1A OR 3 INFECTION AND HAVE PREVIOUSLY BEEN TREATED WITH AN HCV REGIMEN CONTAINING SOFOSBUVIR WITHOUT AN NS5A INHIBITOR
  ✓
  Drug substance
  ✓
  Drug product
- November 16, 2032
  ✓
  Patent use: TREATMENT OF ADULT PATIENTS WITH CHRONIC HCV INFECTION WHO HAVE GENOTYPE 1, 2, 3, 4, 5, OR 6 INFECTION AND HAVE PREVIOUSLY BEEN TREATED WITH AN HCV REGIMEN CONTAINING AN NS5A INHIBITOR
  ✓
  Drug substance
  ✓
  Drug product
- May 16, 2033
  ✓
  Pediatric exclusivity
Antiviral compounds
Patent 8,940,718
Issued: January 27, 2015
Assignee(s): Gilead Pharmasset LLC
The disclosure is related to anti-viral compounds, compositions containing such compounds, and therapeutic methods that include the administration of such compounds, as well as to processes and intermediates useful for preparing such compounds.
Patent expiration dates:
- November 16, 2032
  ✓
  Patent use: TREATMENT OF ADULT PATIENTS WITH CHRONIC HCV INFECTION WHO HAVE GENOTYPE 1, 2, 3, 4, 5, OR 6 INFECTION AND HAVE PREVIOUSLY BEEN TREATED WITH AN HCV REGIMEN CONTAINING AN NS5A INHIBITOR
  ✓
  Drug substance
  ✓
  Drug product
- November 16, 2032
  ✓
  Patent use: TREATMENT OF ADULT PATIENTS WITH CHRONIC HCV INFECTION WHO HAVE GENOTYPE 1A OR 3 INFECTION AND HAVE PREVIOUSLY BEEN TREATED WITH AN HCV REGIMEN CONTAINING SOFOSBUVIR WITHOUT AN NS5A INHIBITOR
  ✓
  Drug substance
  ✓
  Drug product
- May 16, 2033
  ✓
  Pediatric exclusivity
Nucleoside phosphoramidate prodrugs
Patent 8,957,046
Issued: February 17, 2015
Assignee(s): Gilead Pharmasset LLC
Disclosed herein are phosphoramidate prodrugs of nucleoside derivatives for the treatment of viral infections in mammals, which is a compound, its stereoisomer, salt (acid or basic addition salt), hydrate, solvate, or crystalline form thereof, represented by the following structure: Also disclosed are methods of treatment, uses, and processes for preparing each of which utilize the compound represented by formula I.
Patent expiration dates:
- March 21, 2028
  ✓
  Patent use: TREATMENT OF ADULT PATIENTS WITH CHRONIC HCV INFECTION WHO HAVE GENOTYPE 1A OR 3 INFECTION AND HAVE PREVIOUSLY BEEN TREATED WITH AN HCV REGIMEN CONTAINING SOFOSBUVIR WITHOUT AN NS5A INHIBITOR
- March 21, 2028
  ✓
  Patent use: TREATMENT OF ADULT PATIENTS WITH CHRONIC HCV INFECTION WHO HAVE GENOTYPE 1, 2, 3, 4, 5, OR 6 INFECTION AND HAVE PREVIOUSLY BEEN TREATED WITH AN HCV REGIMEN CONTAINING AN NS5A INHIBITOR
Nucleoside phosphoramidate prodrugs
Patent 9,085,573
Issued: July 21, 2015
Assignee(s): GILEAD PHARMASSET LLC
Disclosed herein are phosphoramidate prodrugs of nucleoside derivatives for the treatment of viral infections in mammals, which is a compound, its stereoisomer, salt (acid or basic addition salt), hydrate, solvate, or crystalline form thereof, represented by the following structure: Also disclosed are methods of treatment, uses, and processes for preparing each of which utilize the compound represented by formula I.
Patent expiration dates:
- March 21, 2028
  ✓
  Patent use: TREATMENT OF ADULT PATIENTS WITH CHRONIC HCV INFECTION WHO HAVE GENOTYPE 1A OR 3 INFECTION AND HAVE PREVIOUSLY BEEN TREATED WITH AN HCV REGIMEN CONTAINING SOFOSBUVIR WITHOUT AN NS5A INHIBITOR
  ✓
  Drug substance
  ✓
  Drug product
- March 21, 2028
  ✓
  Patent use: TREATMENT OF ADULT PATIENTS WITH CHRONIC HCV INFECTION WHO HAVE GENOTYPE 1, 2, 3, 4, 5, OR 6 INFECTION AND HAVE PREVIOUSLY BEEN TREATED WITH AN HCV REGIMEN CONTAINING AN NS5A INHIBITOR
  ✓
  Drug substance
  ✓
  Drug product
- September 21, 2028
  ✓
  Pediatric exclusivity
Nucleoside phosphoramidates
Patent 9,284,342
Issued: March 15, 2016
Assignee(s): Gilead Pharmasset LLC
Disclosed herein are nucleoside phosphoramidates and their use as agents for treating viral diseases. These compounds are inhibitors of RNA-dependent RNA viral replication and are useful as inhibitors of HCV NS5B polymerase, as inhibitors of HCV replication and for treatment of hepatitis C infection in mammals.
Patent expiration dates:
- September 13, 2030
  ✓
  Patent use: TREATMENT OF ADULT PATIENTS WITH CHRONIC HCV INFECTION WHO HAVE GENOTYPE 1A OR 3 INFECTION AND HAVE PREVIOUSLY BEEN TREATED WITH AN HCV REGIMEN CONTAINING SOFOSBUVIR WITHOUT AN NS5A INHIBITOR
  ✓
  Drug substance
  ✓
  Drug product
- September 13, 2030
  ✓
  Patent use: TREATMENT OF ADULT PATIENTS WITH CHRONIC HCV INFECTION WHO HAVE GENOTYPE 1, 2, 3, 4, 5, OR 6 INFECTION AND HAVE PREVIOUSLY BEEN TREATED WITH AN HCV REGIMEN CONTAINING AN NS5A INHIBITOR
  ✓
  Drug substance
  ✓
  Drug product
- March 13, 2031
  ✓
  Pediatric exclusivity
Inhibitors of hepatitis C virus
Patent 9,296,782
Issued: March 29, 2016
Assignee(s): Gilead Sciences, Inc.
Compounds of Formula I are disclosed As well as pharmaceutically acceptable salts thereof. Methods of using said compounds and pharmaceutical compositions containing said compounds are also disclosed.
Patent expiration dates:
- July 17, 2034
  ✓
  Drug substance
  ✓
  Drug product
Nucleoside phosphoramidate prodrugs
Patent 9,585,906
Issued: March 7, 2017
Assignee(s): Gilead Pharmasset LLC
Disclosed herein are phosphoramidate prodrugs of nucleoside derivatives for the treatment of viral infections in mammals, which is a compound, its stereoisomer, salt (acid or basic addition salt), hydrate, solvate, or crystalline form thereof, represented by the following structure: Also disclosed are methods of treatment, uses, and processes for preparing each of which utilize the compound represented by formula I.
Patent expiration dates:
- March 21, 2028
  ✓
  Patent use: TREATMENT OF ADULT PATIENTS WITH CHRONIC HCV INFECTION WHO HAVE GENOTYPE 1, 2, 3, 4, 5, OR 6 INFECTION AND HAVE PREVIOUSLY BEEN TREATED WITH AN HCV REGIMEN CONTAINING AN NS5A INHIBITOR
  ✓
  Drug substance
  ✓
  Drug product
- March 21, 2028
  ✓
  Patent use: TREATMENT OF ADULT PATIENTS WITH CHRONIC HCV INFECTION WHO HAVE GENOTYPE 1A OR 3 INFECTION AND HAVE PREVIOUSLY BEEN TREATED WITH AN HCV REGIMEN CONTAINING SOFOSBUVIR WITHOUT AN NS5A INHIBITOR
  ✓
  Drug substance
  ✓
  Drug product
Antiviral compounds
Patent 9,868,745
Issued: January 16, 2018
Assignee(s): Gilead Pharmasset LLC
The disclosure is related to anti-viral compounds, compositions containing such compounds, and therapeutic methods that include the administration of such compounds, as well as to processes and intermediates useful for preparing such compounds.
Patent expiration dates:
- November 16, 2032
  ✓
  Drug substance
  ✓
  Drug product

More about Vosevi (sofosbuvir / velpatasvir / voxilaprevir)

Glossary

Term	Definition
Drug Patent	A drug patent is assigned by the U.S. Patent and Trademark Office and assigns exclusive legal right to the patent holder to protect the proprietary chemical formulation. The patent assigns exclusive legal right to the inventor or patent holder, and may include entities such as the drug brand name, trademark, product dosage form, ingredient formulation, or manufacturing process A patent usually expires 20 years from the date of filing, but can be variable based on many factors, including development of new formulations of the original chemical, and patent infringement litigation.
Drug Exclusivity	Exclusivity is the sole marketing rights granted by the FDA to a manufacturer upon the approval of a drug and may run simultaneously with a patent. Exclusivity periods can run from 180 days to seven years depending upon the circumstance of the exclusivity grant.
RLD	A Reference Listed Drug (RLD) is an approved drug product to which new generic versions are compared to show that they are bioequivalent. A drug company seeking approval to market a generic equivalent must refer to the Reference Listed Drug in its Abbreviated New Drug Application (ANDA). By designating a single reference listed drug as the standard to which all generic versions must be shown to be bioequivalent, FDA hopes to avoid possible significant variations among generic drugs and their brand name counterpart.